Peggy J Ebner1, Li Ding1, Anthony W Kim2, Scott M Atay2, Mimi J Yao1, Omar Toubat1, P Michael McFadden2, Alex A Balekian3, Elizabeth A David4. 1. Keck School of Medicine, University of Southern California, Los Angeles, California. 2. Division of Thoracic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California. 3. Division of Pulmonary and Critical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 4. Division of Thoracic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: elizabeth.david@med.usc.edu.
Abstract
BACKGROUND: Treatment decisions for patients with non-small cell lung cancer (NSCLC) are based on patient and tumor characteristics, including socioeconomic status (SES) factors. The objective was to assess the contribution of SES factors to treatment and outcomes among patients with stage I NSCLC. METHODS: The National Cancer Database was queried for operable patients with stage I NSCLC. Patients were divided into three treatment groups: primary resection (ie, surgery only); nonstandard treatments consisting of chemotherapy with or without radiation; and no therapy. The SES of patients who made up the treatment groups was assessed, and the 5-year survival of all groups was analyzed. RESULTS: The cohort included 69,168 patients with stage I NSCLC. Each of these patients had between zero and five SES risk factors. The factors associated with no surgery were low income, nonwhite race, low high school graduation rate, Medicaid or no insurance, rural residence, and distance less than 12.5 miles from treatment facility. Patients with several SES risk factors have linearly increasing odds of undergoing nonstandard treatments and quadratically increasing odds of having no therapy (for patients with five factors, to odds ratio 4.7; 95% confidence interval, 3.44 to 6.30). Surgery alone was associated with significantly longer 5-year survival (71.8%) compared with nonstandard treatments (22.7%) and no therapy (21.8%; P < .001). CONCLUSIONS: Socioeconomic status factors increase the risk of undergoing guideline discordant therapy for stage I NSCLC. As the number of SES factors increases, the odds of no therapy rises quadratically whereas the odds of nonstandard treatments rises constantly. The surgery only group had significantly longer survival than the nonstandard treatment and no therapy groups.
BACKGROUND: Treatment decisions for patients with non-small cell lung cancer (NSCLC) are based on patient and tumor characteristics, including socioeconomic status (SES) factors. The objective was to assess the contribution of SES factors to treatment and outcomes among patients with stage I NSCLC. METHODS: The National Cancer Database was queried for operable patients with stage I NSCLC. Patients were divided into three treatment groups: primary resection (ie, surgery only); nonstandard treatments consisting of chemotherapy with or without radiation; and no therapy. The SES of patients who made up the treatment groups was assessed, and the 5-year survival of all groups was analyzed. RESULTS: The cohort included 69,168 patients with stage I NSCLC. Each of these patients had between zero and five SES risk factors. The factors associated with no surgery were low income, nonwhite race, low high school graduation rate, Medicaid or no insurance, rural residence, and distance less than 12.5 miles from treatment facility. Patients with several SES risk factors have linearly increasing odds of undergoing nonstandard treatments and quadratically increasing odds of having no therapy (for patients with five factors, to odds ratio 4.7; 95% confidence interval, 3.44 to 6.30). Surgery alone was associated with significantly longer 5-year survival (71.8%) compared with nonstandard treatments (22.7%) and no therapy (21.8%; P < .001). CONCLUSIONS: Socioeconomic status factors increase the risk of undergoing guideline discordant therapy for stage I NSCLC. As the number of SES factors increases, the odds of no therapy rises quadratically whereas the odds of nonstandard treatments rises constantly. The surgery only group had significantly longer survival than the nonstandard treatment and no therapy groups.
Authors: Chi Young Kim; Beong Ki Kim; Yu Jin Kim; Seung Heon Lee; Young Sam Kim; Je Hyeong Kim Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-01-05
Authors: Chinmay Jani; Dominic C Marshall; Harpreet Singh; Richard Goodall; Joseph Shalhoub; Omar Al Omari; Justin D Salciccioli; Carey C Thomson Journal: ERJ Open Res Date: 2021-12-27
Authors: Muhammad Rafiqul Islam; A T M Kamrul Hasan; Nazrina Khatun; Ishrat Nur Ridi; Md Mamun Or Rasheed; Syed Mohammad Ariful Islam; Md Nazmul Karim Journal: PLoS One Date: 2021-12-10 Impact factor: 3.240
Authors: En Cheng; Pamela R Soulos; Melinda L Irwin; Elizabeth M Cespedes Feliciano; Carolyn J Presley; Charles S Fuchs; Jeffrey A Meyerhardt; Cary P Gross Journal: JAMA Netw Open Date: 2021-12-01
Authors: Umit Tapan; Kimberley S Mak; Michelle H Lee; Muhammad Mustafa Qureshi; Kei Suzuki; Peter Everett Journal: J Thorac Dis Date: 2022-08 Impact factor: 3.005
Authors: Bryce D Beutler; Mark B Ulanja; Rohee Krishan; Vijay Aluru; Munachismo L Ndukwu; Molly M Hagen; Zachary D Dupin; Charles E Willyard; Alastair E Moody; Killian Boampong-Konam; Steven C Zell Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302